INT13544

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 1991
Last Reported 2008
Negated 0
Speculated 1
Reported most in Body
Documents 9
Total Number 10
Disease Relevance 6.34
Pain Relevance 1.80

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (LTA) extracellular space (LTA) extracellular region (LTA)
cell-cell signaling (LTA)
Anatomy Link Frequency
B lymphocytes 1
LTA (Homo sapiens)
Pain Link Frequency Relevance Heat
corticosteroid 38 99.84 Very High Very High Very High
Osteoarthritis 2 98.28 Very High Very High Very High
Migraine 166 97.92 Very High Very High Very High
rheumatoid arthritis 6 97.54 Very High Very High Very High
cINOD 2 96.26 Very High Very High Very High
cytokine 7 95.44 Very High Very High Very High
Inflammatory response 2 91.04 High High
Inflammation 19 75.00 Quite High
antagonist 8 50.00 Quite Low
agonist 3 39.76 Quite Low
Disease Link Frequency Relevance Heat
Necrosis 6 100.00 Very High Very High Very High
Cancer 5 100.00 Very High Very High Very High
Immunization 144 98.48 Very High Very High Very High
Diabetes Mellitus 71 98.32 Very High Very High Very High
Osteoarthritis 2 98.28 Very High Very High Very High
Headache 144 97.92 Very High Very High Very High
Chondrocalcinosis 2 97.64 Very High Very High Very High
Rheumatoid Arthritis 6 97.54 Very High Very High Very High
Asthma 78 96.24 Very High Very High Very High
INFLAMMATION 26 96.14 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The TNFSF7 gene (Tumor Necrosis Factor Ligand Superfamily, member 7) localized on C19p13 is a surface antigen found on activated, but not resting, T and B lymphocytes [21].
Localization (localized) of Tumor Necrosis Factor Ligand Superfamily in B lymphocytes associated with necrosis and cancer
1) Confidence 0.78 Published 2008 Journal The Open Neurology Journal Section Body Doc Link PMC2577928 Disease Relevance 1.21 Pain Relevance 0.62
Type 1 diabetic patients with a history of macrovascular complications had higher frequency of the LTA A allele than patients without macrovascular complications (52.7% vs. 44.8%, p?
Localization (allele) of LTA associated with diabetes mellitus
2) Confidence 0.74 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2429972 Disease Relevance 1.41 Pain Relevance 0
(TNFB), localised in the HLA class III region.
Localization (localised) of TNFB
3) Confidence 0.60 Published 2007 Journal J Headache Pain Section Body Doc Link PMC2779399 Disease Relevance 1.29 Pain Relevance 0.59
The effects of sulfasalazine (SASP) and its metabolites sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA) were investigated on release of prostaglandins (PG) and leukotrienes (LT) from synovial tissue of 37 patients with osteoarthritis, chondrocalcinosis and rheumatoid arthritis.
Spec (investigated) Localization (release) of LT associated with chondrocalcinosis, rheumatoid arthritis and osteoarthritis
4) Confidence 0.49 Published 1991 Journal Wien. Klin. Wochenschr. Section Abstract Doc Link 1673814 Disease Relevance 0.37 Pain Relevance 0.10
While nonsteroidal anti-inflammatory drugs, which are used for symptomatic therapy of rheumatoid arthritis, inhibit cyclooxygenase only, SP, the active metabolite of the second line anti-rheumatic drug SASP, inhibits both PG and LT release.
Localization (release) of LT associated with inflammation, rheumatoid arthritis and cinod
5) Confidence 0.49 Published 1991 Journal Wien. Klin. Wochenschr. Section Abstract Doc Link 1673814 Disease Relevance 0.47 Pain Relevance 0.26
After second immunization mean peak IgG titer to LT 3056 (peak fold increase 3.5), mean peak IgA ASC response to LT 0.73, mean peak IgG titer to LPS 1680 (7.9), mean peak IgA ASC response to LPS 13.
Localization (response) of LT associated with immunization
6) Confidence 0.46 Published 2007 Journal Vaccine Section Body Doc Link PMC2652036 Disease Relevance 0.34 Pain Relevance 0
For subjects receiving 108 CFU: After first immunization mean peak IgG titer to LT 2625 (peak fold increase 2.5), mean peak IgA ASC response to LT 0, mean peak IgG titer to LPS 2073 (15.4), mean peak IgA ASC response to LPS 121.
Localization (response) of LT associated with immunization
7) Confidence 0.46 Published 2007 Journal Vaccine Section Body Doc Link PMC2652036 Disease Relevance 0.32 Pain Relevance 0
For the responses to ETEC LT: Amongst the 36 subjects recruited, 67% demonstrated an IgG or IgA immune response against ETEC LT measured either by ELISPOT or ELISA.
Localization (response) of LT
8) Confidence 0.40 Published 2007 Journal Vaccine Section Body Doc Link PMC2652036 Disease Relevance 0.07 Pain Relevance 0
For the responses to ETEC LT: Amongst the 36 subjects recruited, 67% demonstrated an IgG or IgA immune response against ETEC LT measured either by ELISPOT or ELISA.
Localization (response) of LT
9) Confidence 0.40 Published 2007 Journal Vaccine Section Body Doc Link PMC2652036 Disease Relevance 0.06 Pain Relevance 0
Also, according to the 1997 guidelines, the LT modifiers were considered as an alternative to low doses of ICS, cromolyn, nedocromil, or theophylline for patients ?
Localization (doses) of LT associated with corticosteroid
10) Confidence 0.05 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661620 Disease Relevance 0.79 Pain Relevance 0.24

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox